NCT05444920 The Italian Transthyretin Amyloidosis Web-Network
| NCT ID | NCT05444920 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Condition | ATTR Amyloidosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2022-07-13 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2022-07-13 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims, by generating a large registry of patients with ATTR amyloidosis, including data at diagnosis and during follow up, to describe the natural history of ATTR amyloidosis in a real-world setting and to define and validate prognostic models, response criteria applicable at any point of the disease. The registry will also be used for data sharing and to allow the possibility of a close collaboration amongst the amyloidosis experts of the ARTC and all the physicians around the Country involved in the diagnosis and management of systemic amyloidosis. Thanks to the online registry, the diagnostic facility of the ARTC will be made available to requesting physicians.
Eligibility Criteria
Inclusion Criteria: 1. Suspected diagnosis of systemic and localized amyloidosis; 2. age .18 years; 3. ability to understand and willingness to sign an informed consent (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted); 4. planned (or ongoing) follow-up at participating center. Exclusion Criteria: 1\. Diagnosis of light chain (AL) amyloidosis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05444920 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying ATTR Amyloidosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05444920 currently recruiting?
Yes, NCT05444920 is actively recruiting participants. Contact the research team at p.milani@smatteo.pv.it for enrollment information.
Where is the NCT05444920 trial being conducted?
This trial is being conducted at Legnano, Italy, Orbassano, Italy, Ancona, Italy, Bari, Italy and 11 additional locations.
Who is sponsoring the NCT05444920 clinical trial?
NCT05444920 is sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. The trial plans to enroll 1,000 participants.